Newsroom
Press Releases
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in…
Read More
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-…
Read More
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
Read More
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX…
Read More
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES)…
Read More
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual…
Read MoreUCB Stories
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and…
Read More
Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options
Read More
Voices on Value: Prioritizing Patients Now and Into the Future
Read More
CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome…
Read More
Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care
Read More
